Biotechnology

BEONE MEDICINES

BeiGene 2026 Q1 Earnings Soar: Net Profit Surges 178x, Revenue Breaks 10 Billion RMB Barrier

BeiGene's Sorotorac Gets FDA Accelerated Approval, Deepening BCL-2 Layout to Mitigate Single-Product Risk

BeiGene's Brukinsa Approved by FDA

BGI Q1 Profit Surges, Revenue Breaks 10 Billion Yuan

CMBC International and DBS Maintain Buy Rating for BeiGene

Citibank Raises BeiGene's US Stock Target Price to $453

Belayzhizun (BeiJing) Q1 Earnings Exceed Expectations

BeiGene Releases Q1 2026 Financial Report and Revises Financial Guidance

Beyterzelk and Amgen Authorized Products Drive First Quarter 2026 Revenue Growth for BeiGene

BeiGene Adjusts 2026 Full-Year Operating Performance Forecast

BEONE MEDICINES released FY2026 Q1 earnings on May 6 Pre-Market (BJT), actual revenue HKD 11.86 B (forecast HKD 11.26 B), actual EPS HKD 1.1755

BeiGene Secures Global Rights to Huaheng's Tri-Antibody for $20 Million

BEONE MEDICINES to release FY2026 Q1 earnings on May 6 Pre-Market (BJT), forecast revenue HKD 11.27 B

BofA Securities Notes BeiGene's Pharmaceutical Sales Growth Maintains Buy Rating

BeiGene's Wholly-Owned Subsidiary Signs Exclusive Option, License and Collaboration Agreement with Huahui Anjian

BGT Biotechnology Reports First Yearly Profit, Innovation Pharmaceuticals Reach Critical Milestone

BeiGene Announces Revenue and Net Profit for 2025

BeiGene Achieves First Annual Profit, Significant Commercial Progress

BeiGene Submits Application for Zanidatamab and BGB-A317 Combination Therapy

BeiGene's Revenue Grew by 40.2% in 2025 and Achieved Profitability

HINSANG GROUP

RIVERINE CHINA

PASHUN INT RTS

BRAINAURORA-B

SOFTMEDX

GOLDENPOWER

ZHONGKE GROUP

VISION SYNERGY

GEMILANG INTL

GHPC

06160

Citic Securities has reaffirmed its Buy rating for BeOne Medicines Ltd (6160) as of May 12, setting a price target of HK$234.00, while the shares closed at HK$189.90. The analyst consensus for the stock is Strong Buy, with a target consensus of HK$254.33, indicating a potential upside of 33.93%. Additionally, DBS also maintains a Buy rating with a price target of HK$290.00.

Tip Ranks

Beigene

BeOne Medicines

CITIC SEC

CITIC Securities Co., Ltd.

Citic Securities Sticks to Its Buy Rating for BeOne Medicines Ltd (6160)

688235

Yesterday's closing price for BeOne Medicines was HKD 190.5, with an intraday volatility of over 4%. The highest price reached HKD 191.8, while the lowest dipped to HKD 183.3, ultimately closing with a slight decline of 0.05%. The MACD daily line formed a golden cross signal above the zero axis, indicating that bullish momentum is re-accumulating in the previous upward trend, with phase buying pressure building up again. The total trading volume reached HKD 748 million, maintaining an active range as a leading stock in the biotechnology sector, with sustained investor interest. On the news front, the global biotechnology sector has recently gained continuous attention. As one of the most internationalized Chinese innovative pharmaceutical companies, BeOne Medicines' core pipelines such as PD-1 and BTK inhibitors are expected to see significant growth in overseas markets, which remains an important logic for institutional investment. Additionally, the Hong Kong stock market has recently benefited from expectations of diplomatic interactions between the U.S. and China—U.S. President Trump is scheduled to visit China from May 13 to 15, which the market interprets as a temporary easing of U.S.-China relations, likely reducing geopolitical uncertainties in the biopharmaceutical field and providing positive catalysts for companies like BeOne Medicines that have significant business in the U.S. From a technical perspective, BeOne Medicines' current stock price is operating near the 5-day and 10-day moving averages, with the short-term moving average system maintaining a bullish arrangement. Although there was significant volatility during the day, the final closing price remained stable near the opening price, indicating a temporary balance between bullish and bearish forces. After confirming the golden cross above the MACD zero axis, if the trading volume continues to stay above HKD 600 million in the following trading days, the momentum to test previous highs is expected to continue

Technical Forecast

WUXI BIO

AKESO

WuXi Biologics

Pre-market trend | BeOne Medicines (6160.HK) 5/11 bulls accumulate and close flat, is a new round of rally about to start?

In a report released yesterday, from CMBC International maintained a Buy rating on BeOne Medicines Ltd, with a price target of HK$278.85.Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks In a report released on May 7, DBS also maintained a Buy rating on the stock with a HK$290.00 price target.

BeOne Medicines Ltd (6160) Gets a Buy from CMBC International

BGNE

UBS Reaffirms Their Buy Rating on BeOne Medicines Ltd (6160)

businessinsider

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

SPDR S&P Biotech

Ark Genomic Revolution ETF

UBS Reaffirms Their Buy Rating on BeOne Medicines Ltd (6160)

159316

SBIO

513120

UOB Kay Hian has reaffirmed its Buy rating for BeOne Medicines Ltd (6160), setting a price target of HK$257.00, while the stock closed at HK$188.90. The analyst consensus for BeOne Medicines is Strong Buy, with a target consensus of HK$252.79, indicating a potential upside of 33.82%. Additionally, DBS also maintains a Buy rating with a higher price target of HK$290.00.

E Fund Hang Seng SCHK Innovative Drug ETF

ChinaAMC SSE STAR Biology and Medicine ETF

China Southern Hang Seng Biotech ETF(QDII)

Guotai CSI Bio-medicine ETF

ALPS Medical Breakthrough

Huaan Hang Seng Biotech ETF

E Fund CSI Biotechnology Theme ETF

Health Care Select Sector SPDR

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

China Merchants CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Penghua SSE STAR Biology and Medicine ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

iShares US Pharma

ICBCCS SSE STAR Biology and Medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

Tianhong CNI BIOMEDICINE ETF

VG Health

Ping An CSI Medicine and Medical Device Innovation ETF

Penghua CSI HK Connect Health Care Composite ETF

Guotai SSE STAR Brand Name Drug ETF

China Universal 800 Health Care ETF

Bosera Hang Seng Health Care ETF(QDII)

Founder Fubon CSI Medicine and Medical Device Innovation ETF

UOB Kay Hian

UOB Kay Hian Sticks to Their Buy Rating for BeOne Medicines Ltd (6160)

In a report released yesterday, from Bank of China maintained a Buy rating on BeOne Medicines Ltd, with a price target of HK$240.00.Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks In a report released yesterday, DBS also maintained a Buy rating on the stock with a HK$290.00 price target.

BANK OF CHINA

Bank Of China

BOC HONG KONG

Bank of China

Bank of China Sticks to Their Buy Rating for BeOne Medicines Ltd (6160)

01681

09926

CONSUN PHARMA has recently shown a steady upward trend, with an increase of approximately 12.27%. The MACD daily bullish signal is gradually being established, with the fast and slow lines crossing above the zero axis, which usually indicates that the medium-term trend is transitioning from a consolidation phase to an upward breakout. The trading volume is about HKD 72.39 million, which, although not a large absolute amount, has significantly increased compared to the stock's historical average daily volume, indicating a rise in capital participation. The stock price is steadily rising, and the short-term moving averages are beginning to turn upward, forming an initial bullish arrangement. On the news front, the overall recovery trend in the pharmaceutical sector is evident. The Hong Kong stock biopharmaceutical index has stabilized and rebounded, with AKESO rising over 4% on the day and BEONE MEDICINES increasing nearly 3%, showing clear signs of capital returning to the sector. As a leader in the traditional Chinese medicine nephrology field, CONSUN PHARMA has a stable product matrix and excellent cash flow performance, making it a defensive yet flexible choice in the rotation of the pharmaceutical sector. Additionally, the domestic medical insurance policy's supportive stance towards traditional Chinese medicine remains unchanged, and the impact of centralized procurement on exclusive varieties is limited. The company's fundamentals are relatively certain, attracting some funds seeking stable returns. From a technical perspective, the current stock price is operating above the 5-day and 10-day moving averages, with both moving averages trending upward and maintaining a moderate distance, forming a step-like support. If today's trading volume remains above HKD 70 million and holds above the 5-day moving average, the upward trend is expected to continue. Attention should be paid to the previous high-pressure zone above, as a breakthrough may open up new upward space. The correlation between the Hong Kong pharmaceutical sector and the A-share market is worth noting, as the A-share market has also been active in the innovative drug sector recently

CONSUN PHARMA

Pre-market trend | CONSUN PHARMA (1681.HK) 5/6 moderately increased with volume, is capital flowing back into the pharmaceutical sector?

BEONE MEDICINES(06160.HK)

Citic Securities Sticks to Its Buy Rating for BeOne Medicines Ltd (6160)

Pre-market trend | BeOne Medicines (6160.HK) 5/11 bulls accumulate and close flat, is a new round of rally about to start?

BeOne Medicines Ltd (6160) Gets a Buy from CMBC International

UBS Reaffirms Their Buy Rating on BeOne Medicines Ltd (6160)

UOB Kay Hian Sticks to Their Buy Rating for BeOne Medicines Ltd (6160)

Bank of China Sticks to Their Buy Rating for BeOne Medicines Ltd (6160)

Pre-market trend | CONSUN PHARMA (1681.HK) 5/6 moderately increased with volume, is capital flowing back into the pharmaceutical sector?